# Qfitlia™ (fitusiran) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/fitusiran

> The FDA approved Qfitlia™ (fitusiran), sponsored by Sanofi (SNY), on March 28, 2025 for to prevent or reduce the frequency of bleeding episodes in hemophilia A or BPress Release.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Qfitlia™ (fitusiran) FDA approved?

Yes. The FDA approved Qfitlia™ (fitusiran), sponsored by Sanofi (SNY), on March 28, 2025 for to prevent or reduce the frequency of bleeding episodes in hemophilia A or BPress Release. FDA novel drug approvals: "Qfitlia | fitusiran | 3/28/2025 | To prevent or reduce the frequency of bleeding episodes in hemophilia A or BPress ReleaseDrug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/fitusiran)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/fitusiran#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Qfitlia™ (fitusiran) |
| Codes | SAR439774 |
| Sponsor | Sanofi (SNY) https://sec-api.dev/companies/sny/catalysts |
| Indications | To prevent or reduce the frequency of bleeding episodes in hemophilia A or BPress Release, [Hemophilia](https://sec-api.dev/indications/hemophilia) |
| Modality | sirna |
| FDA designations | breakthrough, orphan |

## Timeline

### March 28, 2025: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To prevent or reduce the frequency of bleeding episodes in hemophilia A or BPress Release.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Qfitlia | fitusiran | 3/28/2025 | To prevent or reduce the frequency of bleeding episodes in hemophilia A or BPress ReleaseDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025
- openFDA Drugs@FDA: "NDA219019 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20250328, review_priority STANDARD; sponsor_name GENZYME CORP; product QFITLIA (FITUSIRAN SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219019%22

### August 4, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2/3. Indication: Hemophilia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03974113 (Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-08-04 (ACTUAL); Lead Sponsor Genzyme, a Sanofi Company." https://clinicaltrials.gov/study/NCT03974113

### Aug to Nov 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: Hemophilia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03974113 (Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-08-04 (ACTUAL); Lead Sponsor Genzyme, a Sanofi Company." https://clinicaltrials.gov/study/NCT03974113

### September 14, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Hemophilia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03754790 (Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-14 (ACTUAL); Lead Sponsor Genzyme, a Sanofi Company." https://clinicaltrials.gov/study/NCT03754790

### Sep to Dec 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Hemophilia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03754790 (Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-14 (ACTUAL); Lead Sponsor Genzyme, a Sanofi Company." https://clinicaltrials.gov/study/NCT03754790

### Mar to Jun 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Hemophilia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05662319 (A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-25 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT05662319

### March 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Hemophilia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05662319 (A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-25 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT05662319

### Aug to Nov 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Hemophilia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07285460 (A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-04 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07285460

### August 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Hemophilia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07285460 (A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-04 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07285460

Calendar months: [March 2027](https://sec-api.dev/fda-calendar/2027-03)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/fitusiran.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Qfitlia™ (fitusiran) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/fitusiran

```bibtex
@misc{secapidev_pdufa_fitusiran_20261116,
  title        = {Qfitlia™ (fitusiran) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/fitusiran}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_fitusiran_20261116","title":"Qfitlia™ (fitusiran) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/fitusiran","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
